Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term pc [Prevention & Control]. Found 8 abstracts

Levy MH, Back A, Bazargan S, Benedetti C, Billings JA, Block S, Bruera E, Carducci MA, Dy S, Eberle C, Foley KM, Harris JD, Knight SJ, Milch R, Rhiner M, Slatkin NE, Spiegel D, Sutton L, Urba S, Von Roenn JH, Weinstein SM, National Comprehensive Cancer N. Palliative care. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2006 Sep;4(8):776-818.
Opatt D, Morrow M. The dual role of nipple preservation.[comment]. The Journal of Supportive Oncology. 2006 May;4(5):233-4.
Schnoll RA, Engstrom PF, Subramanian S, Demidov L, Wielt DB. Smoking cessation counseling by Russian oncologists: opportunities for intervention in the Russian Federation. International journal of behavioral medicine. 2006 Jan;13(1):8-15.
Schnoll RA, Engstrom PF, Subramanian S, Demidov L, Wielt DB, Tighiouart M. Prevalence and correlates of tobacco use among Russian cancer patients: implications for the development of smoking cessation interventions at a cancer center in Russia. International journal of behavioral medicine. 2006 Jan;13(1):16-25.
Dushkin H, Schilder RJ. Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology. 2005 Mar;6(2):115-20.
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A, Greenberg RE, Pollack A, Kolenko V, Watkins-Bruner D. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer. BJU international. 2004 May;93(7):955-60.
Feigenberg SJ, Wolk KL, Yang CH, Morris CG, Zlotecki RA. Celecoxib to decrease urinary retention associated with prostate brachytherapy. Brachytherapy. 2003 Jan;2(2):103-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term pc [Prevention & Control]

pc [Prevention & Control] Female Male Middle Aged ad [Administration & Dosage] Prostatic Neoplasms mt [Methods] Adult NIH Research Support-Extramural dt [Drug Therapy] Moscow Smoking Aged Medical Oncology Sulfonamides tu [Therapeutic Use] Treatment Outcome Smoking Cessation Human ae [Adverse Effects] Attitudes Health Knowledge-Practice Female Genital Neoplasms Urinary Retention Carcinogens Risk Assessment 35661-60-0 (N-(fluorenyl-9-methoxycarbonyl)leucine) Piperazines Experimental Mammary Neoplasms 0 (Sulfonamides) 41598-07-6 (Prostaglandin D2) Cytoplasmic and Nuclear Receptors Medical Education-Continuing Logistic Models 0 (Fluorenes) ai [Antagonists & Inhibitors] Methylnitrosourea bi [Biosynthesis] Dinoprostone Pain 0 (15-deoxyprostaglandin J2) rt [Radiotherapy] en [Enzymology] 0 (Anticarcinogenic Agents) Drug Administration Schedule Palliative Care et [Etiology] pa [Pathology] Sprague-Dawley Rats px [Psychology] Brachytherapy Prevalence Non-Steroidal Anti-Inflammatory Agents 363-24-6 (Dinoprostone) Biological Availability Uterine Neoplasms Isoenzymes Motivation Drug Synergism Prostaglandin D2 Neoplasms Prostheses and Implants 0 (Isoenzymes) Comparative Study Cell Division ci [Chemically Induced] 0 (Transcription Factors) me [Metabolism] Prognosis Pyrimidines ed [Education] Colorectal Neoplasms 0 (Piperazines) Self Care EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Apoptosis Ovarian Neoplasms pd [Pharmacology] Patient Care Team Mammaplasty 61-90-5 (Leucine) de [Drug Effects] Prostaglandin-Endoperoxide Synthase Lung Neoplasms Cell Cycle Subcutaneous Mastectomy di [Diagnosis] Anticarcinogenic Agents 152459-95-5 (imatinib) pk [Pharmacokinetics] Nipples Cytoplasmic and Nuclear) 0 (Receptors 0 (Carcinogens) ag [Agonists] Fluorenes Drug Dose-Response Relationship Maximum Tolerated Dose th [Therapy] Directive Counseling 169590-42-5 (celecoxib) mo [Mortality] Vitamins 0 (Cyclooxygenase Inhibitors) Survival Analysis Clinical Competence Risk Factors 684-93-5 (Methylnitrosourea) su [Surgery] Rats Herbal Medicine Foreign-Body Reaction 0 (Pyrimidines) 80 and over Aged Dietary Supplements Physician's Practice Patterns aa [Analogs & Derivatives] Cyclooxygenase Inhibitors Breast Neoplasms EC 1-14-99-1 (cyclooxygenase 2) Local Neoplasm Recurrence Leucine Risk-Taking Neoplasm Staging ep [Epidemiology] ph [Physiology] Transcription Factors
Last updated on Monday, May 04, 2020